Genmab A+s

Janssen Biotech, Inc.

Tahamtan Ahmadi

Brian Elliott

Esther C W Breij

Christopher W L Chiu

Ida Hiemstra

Maria N Jure-Kunkel

Amy Sasser

Christopher Chiu

Niels Van De Donk

Tuna Mutis

Henk Lokhorst

Dena Demarco

Roberto Oliveri

Tommy Li

Manish Gupta

Ming Qi

Jordan Schecter

Tineke Casneuf

Jenny Jianlin Chen

Ada Azaryan

Henk M Lokhorst

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

Bispecific antibodies against CD3 and CD20

Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma

Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

Methods of treating high risk multiple myeloma

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.

Growing community of inventors

Rydal, PA, United States of America

Tahamtan Ahmadi